SK284049B6 - Orálny prostriedok a spôsob jeho prípravy - Google Patents

Orálny prostriedok a spôsob jeho prípravy Download PDF

Info

Publication number: SK284049B6
Authority: SK; Slovakia
Prior art keywords: cross; composition; cellulose derivative; entacapone; linked cellulose
Prior art date: 1998-09-14

Application number

SK307-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK3072001A3 (en

Inventor

Kari Vahervuo

Original Assignee

Orion Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-14

Filing date

1999-09-13

Publication date

2004-08-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22542186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284049(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-13 Application filed by Orion Corporation filed Critical Orion Corporation

2002-05-09 Publication of SK3072001A3 publication Critical patent/SK3072001A3/sk

2004-08-03 Publication of SK284049B6 publication Critical patent/SK284049B6/sk

Links

JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 title claims abstract description 44
229960003337 entacapone Drugs 0.000 title claims abstract description 44
229920002678 cellulose Polymers 0.000 title claims abstract description 39
239000001913 cellulose Substances 0.000 title claims abstract description 39
UPMRZALMHVUCIN-UHFFFAOYSA-N Nitecapone Chemical compound CC(=O)C(C(C)=O)=CC1=CC(O)=C(O)C([N+]([O-])=O)=C1 UPMRZALMHVUCIN-UHFFFAOYSA-N 0.000 title claims abstract description 25
229950008980 nitecapone Drugs 0.000 title claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 title description 3
239000000203 mixture Substances 0.000 claims abstract description 71
150000003839 salts Chemical class 0.000 claims abstract description 26
235000010980 cellulose Nutrition 0.000 claims description 35
229920002785 Croscarmellose sodium Polymers 0.000 claims description 16
238000000034 method Methods 0.000 claims description 15
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 14
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
229960001681 croscarmellose sodium Drugs 0.000 claims description 11
239000008187 granular material Substances 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
239000000314 lubricant Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
238000009472 formulation Methods 0.000 description 12
239000003826 tablet Substances 0.000 description 11
239000011777 magnesium Substances 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
238000004090 dissolution Methods 0.000 description 7
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
229930195725 Mannitol Natural products 0.000 description 6
239000007884 disintegrant Substances 0.000 description 6
239000000594 mannitol Substances 0.000 description 6
235000010355 mannitol Nutrition 0.000 description 6
239000003085 diluting agent Substances 0.000 description 5
230000002708 enhancing effect Effects 0.000 description 5
239000011230 binding agent Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000008137 solubility enhancer Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000007916 tablet composition Substances 0.000 description 4
102000006378 Catechol O-methyltransferase Human genes 0.000 description 3
108020002739 Catechol O-methyltransferase Proteins 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000007922 dissolution test Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
-1 3,4-dihydroxy-5-nitrobenzylidene Chemical group 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
SGHLQSOQZHDBIS-UHFFFAOYSA-N C(C)N(C(C(=CC1=CCCC(=C1)[N+](=O)[O-])C#N)=O)CC Chemical compound C(C)N(C(C(=CC1=CCCC(=C1)[N+](=O)[O-])C#N)=O)CC SGHLQSOQZHDBIS-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940005928 entacapone 200 mg Drugs 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000010773 plant oil Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

SK307-2001A 1998-09-14 1999-09-13 Orálny prostriedok a spôsob jeho prípravy SK284049B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/152,263 US6599530B2 (en)	1998-09-14	1998-09-14	Oral compacted composition comprising catechol derivatives
PCT/FI1999/000740 WO2000015196A1 (en)	1998-09-14	1999-09-13	Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative

Publications (2)

Publication Number	Publication Date
SK3072001A3 SK3072001A3 (en)	2002-05-09
SK284049B6 true SK284049B6 (sk)	2004-08-03

Family

ID=22542186

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK307-2001A SK284049B6 (sk)	1998-09-14	1999-09-13	Orálny prostriedok a spôsob jeho prípravy

Country Status (39)

Country	Link
US (1)	US6599530B2 (da)
EP (1)	EP1112065B1 (da)
JP (1)	JP4619537B2 (da)
KR (1)	KR100732187B1 (da)
CN (1)	CN1151778C (da)
AR (1)	AR021806A1 (da)
AT (1)	ATE256454T1 (da)
AU (1)	AU746889B2 (da)
BG (1)	BG65041B1 (da)
BR (1)	BR9913681A (da)
CA (1)	CA2342634C (da)
CO (1)	CO5130008A1 (da)
CZ (1)	CZ293960B6 (da)
DE (1)	DE69913714T2 (da)
DK (1)	DK1112065T3 (da)
EA (1)	EA003282B1 (da)
EE (1)	EE04657B1 (da)
ES (1)	ES2213381T3 (da)
GE (1)	GEP20033062B (da)
HK (1)	HK1039750B (da)
HR (1)	HRP20010277B1 (da)
HU (1)	HU228910B1 (da)
ID (1)	ID29026A (da)
IL (1)	IL141681A0 (da)
ME (1)	ME00706B (da)
MY (1)	MY124394A (da)
NO (1)	NO331641B1 (da)
NZ (1)	NZ510583A (da)
PE (1)	PE20001060A1 (da)
PL (1)	PL193454B1 (da)
PT (1)	PT1112065E (da)
RS (1)	RS49723B (da)
SI (1)	SI1112065T1 (da)
SK (1)	SK284049B6 (da)
TR (1)	TR200100752T2 (da)
TW (1)	TWI222367B (da)
UA (1)	UA73925C2 (da)
WO (1)	WO2000015196A1 (da)
ZA (1)	ZA200102084B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
FI20000635A0 (fi) *	2000-03-17	2000-03-17	Orion Yhtymae Oyj	COMT-inhibiittoreiden käyttö analgeettina
US7659253B2 (en) *	2002-02-22	2010-02-09	Shire Llc	Abuse-resistant amphetamine prodrugs
US20060173074A1 (en)	2004-11-10	2006-08-03	Juha Ellmen	Treatment of restless legs syndrome
AU2012216377C1 (en) *	2005-06-08	2013-10-10	Orion Corporation	Oral dosage form
PL1896006T3 (pl) *	2005-06-08	2010-03-31	Orion Corp	Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego
WO2007069274A2 (en) *	2005-11-09	2007-06-21	Torrent Pharmaceuticals Limited	Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
EP1991241A4 (en) *	2006-02-23	2009-07-08	Iomedix Sleep Internat Srl	COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING
GB2429645A (en) *	2006-03-10	2007-03-07	Sekhsaria Chemicals Ltd	Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
WO2007113371A1 (en) *	2006-03-31	2007-10-11	Iprbox Oy	Pharmaceutical composition and preparation method thereof
CA2572004A1 (en) *	2006-12-08	2008-06-08	Bernard Charles Sherman	Tablets comprising entacapone and crospovidone
EP1946756A1 (en) *	2007-01-17	2008-07-23	Revotar Biopharmaceuticals AG	Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
EP2252284B1 (en) *	2008-02-06	2011-05-25	Wockhardt Research Centre	Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
MX2010008707A (es) *	2008-02-06	2011-03-25	Wockhardt Ltd	Composiciones farmaceuticas de entacapona comicronizada con alcoholes de azucar.
CA2734972C (en) *	2008-08-22	2017-03-28	Wockhardt Research Centre	An extended release pharmaceutical composition of entacapone or salts thereof
US9750702B2 (en) *	2009-12-25	2017-09-05	Innopharmax, Inc.	Pharmaceutical composition for treating parkinson's disease and preparation method thereof
WO2012147099A1 (en)	2011-04-25	2012-11-01	Suven Nishtaa Pharma Pvt. Ltd.	Pharmaceutical compositions of levodopa, carbidopa and entacapone
CA2833443C (en) *	2011-04-26	2017-11-07	Innopharmax, Inc.	A composition of entacapone
RU2017120184A (ru)	2014-11-28	2018-12-28	БИАЛ - ПОРТЕЛА ЭНД Ка, С.А.	Лекарства для замедления течения болезни паркинсона
CA2937365C (en)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3275433A1 (en) *	2016-07-29	2018-01-31	Som Innovation Biotech S.L.	Sustained release composition comprising micronized tolcapone
CN106236720A (zh) *	2016-08-29	2016-12-21	海南通用康力制药有限公司	一种恩他卡朋的药物组合物及其制备方法
CN113274362A (zh) *	2021-03-31	2021-08-20	海南通用康力制药有限公司	恩他卡朋片的生产方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR880701098A (ko) *	1986-04-01	1988-07-25	로버어트 에이 아미테이지	메틸프레드니솔론/소디움 카르복시메틸 전분 정제 조성물
US5283352A (en) *	1986-11-28	1994-02-01	Orion-Yhtyma Oy	Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
YU213587A (en) *	1986-11-28	1989-06-30	Orion Yhtymae Oy	Process for obtaining new pharmacologic active cateholic derivatives
US5489614A (en) *	1987-11-27	1996-02-06	Orion-Yhtyma Oy	Catechol derivatives, their physiologically acceptable salts, esters and use
US5380535A (en) *	1991-05-28	1995-01-10	Geyer; Robert P.	Chewable drug-delivery compositions and methods for preparing the same
TW430561B (en) *	1995-12-20	2001-04-21	Gea Farmaceutisk Fabrik As	Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet

1998
- 1998-09-14 US US09/152,263 patent/US6599530B2/en not_active Expired - Lifetime
1999
- 1999-09-01 TW TW088115016A patent/TWI222367B/zh not_active IP Right Cessation
- 1999-09-06 MY MYPI99003853A patent/MY124394A/en unknown
- 1999-09-09 PE PE1999000912A patent/PE20001060A1/es not_active IP Right Cessation
- 1999-09-13 PL PL99346618A patent/PL193454B1/pl unknown
- 1999-09-13 DE DE69913714T patent/DE69913714T2/de not_active Expired - Lifetime
- 1999-09-13 HU HU0103454A patent/HU228910B1/hu unknown
- 1999-09-13 EA EA200100354A patent/EA003282B1/ru not_active IP Right Cessation
- 1999-09-13 IL IL14168199A patent/IL141681A0/xx not_active IP Right Cessation
- 1999-09-13 EP EP99944655A patent/EP1112065B1/en not_active Expired - Lifetime
- 1999-09-13 HR HR20010277A patent/HRP20010277B1/xx not_active IP Right Cessation
- 1999-09-13 TR TR2001/00752T patent/TR200100752T2/xx unknown
- 1999-09-13 CA CA002342634A patent/CA2342634C/en not_active Expired - Lifetime
- 1999-09-13 JP JP2000569780A patent/JP4619537B2/ja not_active Expired - Lifetime
- 1999-09-13 CO CO99057858A patent/CO5130008A1/es unknown
- 1999-09-13 PT PT99944655T patent/PT1112065E/pt unknown
- 1999-09-13 BR BR9913681-3A patent/BR9913681A/pt not_active Application Discontinuation
- 1999-09-13 WO PCT/FI1999/000740 patent/WO2000015196A1/en not_active Ceased
- 1999-09-13 HK HK02101311.8A patent/HK1039750B/zh not_active IP Right Cessation
- 1999-09-13 CN CNB998109134A patent/CN1151778C/zh not_active Expired - Lifetime
- 1999-09-13 NZ NZ510583A patent/NZ510583A/xx not_active IP Right Cessation
- 1999-09-13 ID IDW20010795A patent/ID29026A/id unknown
- 1999-09-13 RS YUP-193/01A patent/RS49723B/sr unknown
- 1999-09-13 ES ES99944655T patent/ES2213381T3/es not_active Expired - Lifetime
- 1999-09-13 AU AU57482/99A patent/AU746889B2/en not_active Expired
- 1999-09-13 UA UA2001042521A patent/UA73925C2/uk unknown
- 1999-09-13 KR KR1020017003245A patent/KR100732187B1/ko not_active Expired - Lifetime
- 1999-09-13 ME MEP-2001-193A patent/ME00706B/me unknown
- 1999-09-13 EE EEP200100147A patent/EE04657B1/xx unknown
- 1999-09-13 CZ CZ2001792A patent/CZ293960B6/cs not_active IP Right Cessation
- 1999-09-13 GE GEAP19995853A patent/GEP20033062B/en unknown
- 1999-09-13 SI SI9930508T patent/SI1112065T1/xx unknown
- 1999-09-13 DK DK99944655T patent/DK1112065T3/da active
- 1999-09-13 AT AT99944655T patent/ATE256454T1/de active
- 1999-09-13 SK SK307-2001A patent/SK284049B6/sk not_active IP Right Cessation
- 1999-09-14 AR ARP990104612A patent/AR021806A1/es active IP Right Grant
2001
- 2001-03-13 NO NO20011278A patent/NO331641B1/no not_active IP Right Cessation
- 2001-03-13 ZA ZA200102084A patent/ZA200102084B/en unknown
- 2001-04-11 BG BG105436A patent/BG65041B1/bg unknown

Also Published As

Publication number	Publication date
HK1039750A1 (en)	2002-05-10
KR100732187B1 (ko)	2007-06-27
HRP20010277A2 (en)	2002-06-30
TR200100752T2 (tr)	2001-10-22
ATE256454T1 (de)	2004-01-15
HRP20010277B1 (hr)	2010-10-31
HUP0103454A2 (hu)	2002-01-28
JP2002524493A (ja)	2002-08-06
CO5130008A1 (es)	2002-02-27
NO20011278L (no)	2001-03-13
PL346618A1 (en)	2002-02-25
SK3072001A3 (en)	2002-05-09
HK1039750B (zh)	2005-02-18
ZA200102084B (en)	2002-06-13
EE04657B1 (et)	2006-08-15
UA73925C2 (uk)	2005-10-17
DE69913714D1 (de)	2004-01-29
CA2342634A1 (en)	2000-03-23
EP1112065B1 (en)	2003-12-17
NO331641B1 (no)	2012-02-13
EP1112065A1 (en)	2001-07-04
PL193454B1 (pl)	2007-02-28
BR9913681A (pt)	2001-06-05
PE20001060A1 (es)	2000-10-20
AU5748299A (en)	2000-04-03
CA2342634C (en)	2008-01-29
AR021806A1 (es)	2002-08-07
PT1112065E (pt)	2004-04-30
ES2213381T3 (es)	2004-08-16
AU746889B2 (en)	2002-05-02
DK1112065T3 (da)	2004-04-05
BG105436A (en)	2001-11-30
IL141681A0 (en)	2002-03-10
KR20010075084A (ko)	2001-08-09
EA200100354A1 (ru)	2001-08-27
EE200100147A (et)	2002-06-17
BG65041B1 (bg)	2007-01-31
YU19301A (sh)	2003-02-28
ID29026A (id)	2001-07-26
JP4619537B2 (ja)	2011-01-26
SI1112065T1 (en)	2004-04-30
US6599530B2 (en)	2003-07-29
EA003282B1 (ru)	2003-04-24
RS49723B (sr)	2007-12-31
ME00706B (me)	2007-12-31
CN1151778C (zh)	2004-06-02
NO20011278D0 (no)	2001-03-13
NZ510583A (en)	2002-09-27
HUP0103454A3 (en)	2003-11-28
GEP20033062B (en)	2003-09-25
TWI222367B (en)	2004-10-21
DE69913714T2 (de)	2004-10-07
WO2000015196A1 (en)	2000-03-23
HU228910B1 (en)	2013-06-28
CZ2001792A3 (cs)	2001-08-15
US20020132009A1 (en)	2002-09-19
MY124394A (en)	2006-06-30
CN1319005A (zh)	2001-10-24
CZ293960B6 (cs)	2004-08-18

Legal Events

Date	Code	Title	Description
2019-11-05	MK4A	Expiry of patent	Expiry date: 20190913

Publication	Publication Date	Title
SK284049B6 (sk)	2004-08-03	Orálny prostriedok a spôsob jeho prípravy
AU2019272064B2 (en)	2021-11-18	High dosage strength tablets of rucaparib
US20030158261A1 (en)	2003-08-21	Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20040062800A1 (en)	2004-04-01	Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
JPH11512736A (ja)	1999-11-02	Ｎ−プロパルギル−１−アミノインダンを含有する安定な組成物
CA2483199A1 (en)	2003-11-06	High drug load tablet of imatinib
EP1321142A1 (en)	2003-06-25	Solid pharmaceutical composition for oral administration of Tegaserod
CA2471715A1 (en)	2003-07-17	A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
JPH04224514A (ja)	1992-08-13	薬物のタブレット組成物およびその製造法
EP2293791B1 (en)	2011-11-23	Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
US20030229101A1 (en)	2003-12-11	Tablets comprising ciprofloxacin hydrochloride
KR100546047B1 (ko)	2006-01-24	디히드로피리딘계 화합물의 서방출성 제제 및 그 제조방법
CA2343949A1 (en)	2002-10-12	Benazepril hydrochloride tablet formulations
MXPA01002650A (en)	2002-05-09	Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
EP3843702A1 (en)	2021-07-07	Immediate release fixed-dose combination of memantine and donepezil
ZA200405079B (en)	2005-06-27	A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof.